TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma

International Journal of Molecular Medicine
Cuiyun LiGuilong Wang

Abstract

In the past decades, chemotherapy has resulted in improved outcomes for patients with osteosarcoma. However, resistance to chemotherapy often leads to poor prognoses. Cisplatin is a standard drug for osteosarcoma therapy, and chemoresistance to cisplatin in osteosarcoma limits the effectiveness of chemotherapy drugs. Transglutaminase 2 (TGM2) is a member of the transglutaminase family, and it is reported to be associated with chemoresistance in various types of cancer. The present study aimed to investigate the function of TGM2 in regulating chemosensitivity of osteosarcoma cells to cisplatin. For in vitro experiments, a cisplatin‑resistant osteosarcoma cell line (Saos2‑CIS‑R) was established, and TGM2 was demonstrated to be upregulated in the resistant Saos2‑CIS‑R cells compared with the normal Saos2 cells. The present study also revealed that TGM2 was associated with chemoresistance to cisplatin in osteosarcoma cells, and knockdown of TGM2 enhanced their chemosensitivity. In addition, TGM2 was demonstrated to affect the chemosensitivity of osteosarcoma cells via regulation of the activation of mitogen‑activated protein kinase and AKT serine/threonine kinase pathways. Expression of BCL2 apoptosis regulator, BCL2 associated X a...Continue Reading

References

Aug 1, 1994·International Journal of Cancer. Journal International Du Cancer·K Mehta
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jan 11, 2005·The Journal of Pathology·D B Longley, P G Johnston
Jul 11, 2006·Clinical & Experimental Metastasis·Christian F SingerAmbros V Huber
Nov 23, 2006·Proceedings of the National Academy of Sciences of the United States of America·Marc A AntonyakRichard A Cerione
Jan 19, 2008·Nature Reviews. Cancer·Anthony G Letai
Jul 18, 2008·Cancer Research·Jee Young HwangAnil K Sood
Sep 19, 2009·Journal of Cancer Research and Clinical Oncology·Kang-Seo ParkKyeong-Man Hong
Mar 11, 2010·Biochemical and Biophysical Research Communications·Dong-Jun PengGen Sheng Wu
Jun 10, 2010·Cancer Research·François-Xavier DieudonnéDominique Modrowski
Mar 1, 2012·International Review of Cell and Molecular Biology·Maria V Nurminskaya, Alexey M Belkin
Sep 26, 2013·Nature Reviews. Cancer·Caitriona HolohanPatrick G Johnston
Oct 16, 2013·International Journal of Molecular Medicine·Yu-Xin LiaoZheng-Dong Cai
Nov 23, 2013·Biomolecules & Therapeutics·Hye Ja Lee, Chang Hoon Lee
Dec 18, 2013·International Journal of Molecular Medicine·Zhifang ZhaoHuimin Tao
Dec 25, 2013·International Journal of Molecular Medicine·Heng WangWen Zhao Chen
Apr 26, 2014·Oncology Letters·Hongtao HeJun Huang
Jul 25, 2014·European Journal of Pharmacology·Shaloam Dasari, Paul Bernard Tchounwou
Jan 7, 2015·Cell Biochemistry and Biophysics·Wei WangDong-Sheng Zhou
Feb 11, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Suoyuan LiZhengdong Cai
Sep 10, 2016·ACS Central Science·Rachel C BothamPaul J Hergenrother

❮ Previous
Next ❯

Citations

Oct 16, 2021·Pharmacological Reports : PR·Mohamad Zahid KasiramSarina Sulong
Dec 25, 2021·Frontiers in Chemistry·Eoin MoynihanDiego Montagner

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR
protein assay
gene knockdown

Software Mentioned

Quantity One
Image
Pro Plus
SPSS
BLAST

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.